WAVE Life Sciences (NASDAQ:WVE) CFO Sells $1,002,221.08 in Stock

by · The Cerbat Gem

WAVE Life Sciences Ltd. (NASDAQ:WVE – Get Free Report) CFO Kyle Moran sold 50,036 shares of the firm’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $20.03, for a total transaction of $1,002,221.08. Following the completion of the transaction, the chief financial officer owned 89,218 shares of the company’s stock, valued at approximately $1,787,036.54. This trade represents a 35.93% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Kyle Moran also recently made the following trade(s):

  • On Monday, December 8th, Kyle Moran sold 210,000 shares of WAVE Life Sciences stock. The stock was sold at an average price of $14.77, for a total transaction of $3,101,700.00.

WAVE Life Sciences Stock Down 5.1%

NASDAQ WVE traded down $1.08 on Wednesday, hitting $20.23. The company’s stock had a trading volume of 17,639,147 shares, compared to its average volume of 11,192,010. WAVE Life Sciences Ltd. has a 1-year low of $5.28 and a 1-year high of $21.73. The company’s 50-day moving average is $8.27 and its 200 day moving average is $7.90. The firm has a market cap of $3.38 billion, a PE ratio of -26.97 and a beta of -1.72.

WAVE Life Sciences (NASDAQ:WVE – Get Free Report) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02). WAVE Life Sciences had a negative return on equity of 75.61% and a negative net margin of 111.64%.The business had revenue of $7.61 million for the quarter, compared to analyst estimates of $9.85 million. On average, equities analysts expect that WAVE Life Sciences Ltd. will post -1.14 EPS for the current year.

Institutional Investors Weigh In On WAVE Life Sciences

Several large investors have recently added to or reduced their stakes in WVE. CIBC Bancorp USA Inc. bought a new stake in WAVE Life Sciences in the third quarter worth approximately $87,000. Polar Capital Holdings Plc boosted its holdings in shares of WAVE Life Sciences by 5.9% during the 3rd quarter. Polar Capital Holdings Plc now owns 1,062,276 shares of the company’s stock worth $7,776,000 after buying an additional 58,776 shares in the last quarter. HighVista Strategies LLC grew its position in shares of WAVE Life Sciences by 64.8% during the 3rd quarter. HighVista Strategies LLC now owns 59,261 shares of the company’s stock worth $434,000 after buying an additional 23,303 shares during the period. Bank of America Corp DE increased its stake in shares of WAVE Life Sciences by 3.0% in the 3rd quarter. Bank of America Corp DE now owns 665,150 shares of the company’s stock valued at $4,869,000 after acquiring an additional 19,590 shares in the last quarter. Finally, Ameriprise Financial Inc. bought a new stake in shares of WAVE Life Sciences in the 3rd quarter valued at $790,000. Institutional investors and hedge funds own 89.73% of the company’s stock.

Analysts Set New Price Targets

WVE has been the subject of several recent research reports. Wedbush increased their price target on WAVE Life Sciences from $18.00 to $20.00 and gave the company an “outperform” rating in a research note on Tuesday, November 11th. Cantor Fitzgerald lifted their price objective on WAVE Life Sciences from $12.00 to $34.00 and gave the stock an “overweight” rating in a research note on Tuesday. Royal Bank Of Canada raised shares of WAVE Life Sciences from a “sector perform” rating to an “outperform” rating and increased their target price for the company from $9.00 to $27.00 in a research report on Monday. Citigroup raised their price target on shares of WAVE Life Sciences from $16.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, B. Riley restated a “buy” rating on shares of WAVE Life Sciences in a research report on Thursday, September 4th. Twelve investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, WAVE Life Sciences presently has an average rating of “Moderate Buy” and an average price target of $27.46.

View Our Latest Report on WVE

WAVE Life Sciences Company Profile

(Get Free Report)

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.

Read More